#Novartis has added a #Tcellengager (TCE) developed by China's #AbogenBiosciences for #autoimmunedisorders in a deal that could be worth over $7.5 billion.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#Novartis has added a #Tcellengager (TCE) developed by China's #AbogenBiosciences for #autoimmunedisorders in a deal that could be worth over $7.5 billion.
@pharmaphorum.bsky.social#GSK has continued its drive to bulk up its #pipeline, taking global rights to a #Tcellengager (TCE) for #multiplemyeloma, developed by China's #ChimagenBiosciences, for up to $750 million.